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Summary.-The extent of tumour, cell kill, produced by treating B16 melanomas
with vincristine, cyclophosphamide, 5-fluorouracil and y-rays, alone and in com-
bination, was determined using an in vitro colony assay.
Cell kill by vincristine was revealed as a reduction in the yield of cells obtained
by trypsinization, and as a decrease in the colony-forming ability of the extracted
cells. The reduction in cell yield was interpreted as evidence of rapid cell lysis. Cyclo-
phosphamide and y-rays also reduced both cell yield and surviving fraction, but in
this case the small decrease in cell yield was due to an increase in cell volume. FU
had no effect on cell yield, but surviving fraction was reduced. Tumour weight was
also measured, and used in conjunction with cell yield and surviving fraction data to
calculate thefraction ofsurviving cellsper tumour following treatment with the agents.
In combination studies, single doses of two different cytotoxic agents were given
either simultaneously, or up to 24 h apart in either sequence, and assays were per-
formed 24 h after the second drug was given. Combinations of vincristine + cyclo-
phosphamide and 5-fluorouracil + y-rays were chosen because they had been shown
by other workers to exhibit marked schedule dependency, including considerable
potentiation, against leukaemic cell lines. However, in the B16 melanoma there was
no evidence of schedule-dependent cell killing with either of these combinations.
For all sequences studied, the fraction of surviving cells per tumour was slightly
greater than the predicted additive response calculated from single-drug controls.
TREATMENT with combinations of anti-
tumour agents has significantly improved
the response rates for a variety of human
tumours. A combination may be more
effective than the best single agent for
three generalreasons: because the separate
agents have different limiting toxicities
and can therefore be combined at doses
close to their maximum single-agent
levels; because one agent deals with
disease in a part of the body which is
missed by other agents; or because some
form of potentiation exists between the
agents in their action against tumour
cells, to a greater extent than against
normal cells. The work described in this
paper is concerned with the question of
potentiation. We have employed the
approach which has been very effectively
used by Valeriote and co-workers (Vietti,
Eggerding and Valeriote, 1971; Medoff,
Schlessinger and Kobayashi, 1973; Vietti,
Valeriote and Dale, 1974; Medoff et al.,
1974; Razek, Vietti and Valeriote, 1974;
Edelstein, Vietti and Valeriote, 1974,
1975) in their studies on L1210 leukaemia
and transplanted AKR lymphoma. Our
objective has been to investigate whether
the potentiation that they have observed
can also be found in a non-lymphoid
tumour. The B16 melanoma was selected
for the present work because it is a tumour
for which there is an efficient clonogenic
assay. The selection of the combinations,
vincristine and cyclophosphamide and
5-fluorouracil and low-LET radiation, wasLACK OF POTENTIATION BETWEEN CYTOTOXIC AGENTS
based upon the high degrees of potentia-
tion found by Razek et al. (1974) and
Vietti et al. (1971) with these combina-
tions, and on preliminary studies which
showed that in terms of clonogenic cell
survival these agents are effective against
the B16 melanoma when administered
individually.
MATERIALS AND METHODS
Drugs.-Vincristine sulphate (VCR, Onco-
vin) was obtained from Eli Lilly and Co.
(Basingstoke, England) in 1-mg vials. It was
dissolved for injection, in sterile 015M NaCl
and, if stored at 40C, there was no detectable
loss of activity over 14 days.
Cyclophosphamide (CP, Endoxana) was
supplied in 100-mg vials by Ward Blenkinsop
Pharmaceuticals Ltd (Bracknell, England).
It was dissolved for injection in 0-15M NaCl
and was always used within 3 h of being
prepared. If stored at 4TC there was no
detectable loss of potency during this period.
5-Fluorouracil (FU, Roche) was obtained
in 250-mg vials from Roche Products Ltd
(Welwyn Garden City, Hertfordshire). It was
in the form of the tris-(hydroxymethyl)
aminomethane salt dissolved in wateL, and
was diluted for injection with phosphate
buffered saline (PBS, Dulbecco and Vogt,
1954).
All three agents were injected by the i.p.
route.
Irradiation.-The irradiation of tumours
in vivo was performed using 60Co y-rays at a
range which gave an air-dose rate of approxi-
mately 300 Roentgens (R)/min. Radiation
doses were converted to rad by assuming that
exposuretooneroentgenproducesantabsorbed
dose in soft tissue of -0-94 rad. Tumour-
bearing mice were given whole-body irradia-
tion while conscious, but constrained in
perforated perspex boxes. To reduce dose
variations the boxes were rotated through
1800 half-way through each irradiation.
Dosimetry was performed using a Baldwin-
Farmer sub-standard dosemeter.
Mice.-Female C57BL mice were obtained
from the Institute of Cancer Research breed-
ing centre. Theywere used when 8 to 10 weeks
old and weighed 20 to 25 g each.
Tumour.-The B16 melanoma used for this
work was obtained from the Roscoe B.
Jackson Memorial Laboratory (Bar Harbor,
Maine, U.S.A.) in 1970. Since then it has been
passaged in C57BL mice, and for a time it
was stored in liquid N2. For transplantation,
the tumour was dissected out, chopped
finely with crossed scalpels and homogenized
by forcing it through syringe needles of
decreasing diameter. The homogenate was
then diluted with 10 volumes of PBS and the
largertissuefragmentswerecollectedbygentle
centrifugation. The pellet was resuspended
in 5 volumes of Ham's F12 culture medium
(Gibco-Biocult Ltd, Paisley, Scotland) con-
taining 20% foetal calf serum (Gibco-Biocult
Ltd) and antibiotics (60 ,ug/ml sodium benzyl
penicillin, 100 ,ug/ml streptomycin sulphate
and 50 p,g/ml neomycin sulphate).
The mice were injected s.c. with 0 05 ml of
homogenate into each flank and used for
experiments 14 to 18 days later. Only those
with 2 tumours of uniform size were selected
and allocated into groups of 2 animals.
Within each experiment the variation inmean
tumour diameter was less than 20%, but
from one experiment to another the mean
diameterofthetumoursvariedfrom5to8mm.
Preparation of cell suspension.-Mice were
killed with ether. Their tumours were dis-
sected out aseptically, weighed, finelychopped
with crossed scalpels and washed with 20 ml
ofPBS. Thetumourfragments wereincubated
in 20 ml of PBS containing trypsin at 2 mg/
ml (Bacto-trypsin, Difco Laboratories,
Detroit, Mich., U.S.A.) and DNase at
0.1 mg/ml (deoxyribonucleate oligonucleo-
tide hydrolase, Sigma Chemical Co., St Louis,
Mo. U.S.A.) for 10 min at 37°C. At the enid
of this incubation, the tissue fragments were
allowed to settle and the supernatant
discarded. A further 20 ml of PBS containing
fresh trypsin and DNase was added to the
tissue fragments and they were incubated
again, this time for 45 min with continuous
gentle agitation.
At the end of the second incubation the
suspension was given 10 vigorous shakes to
dislodge loosely attached cells from the
remaining very small tumour fragments.
The suspension was filtered through monofil
polyester mesh (35 ,um aperture, Henry
Simon Ltd, Stockport, England) and the
single cells in the filtrate were collected by
centrifugation. They were washed once with
20 ml of Ham's F12 culture medium, centri-
fuged, and resuspended in 10 ml of the same
medium. To discourage aggregation of cells,
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DNase was added at a final concentration
of 0-025 mg/ml.
The cell suspensions were diluted with
culture medium and counted using a haemo-
cytometer. The mean cell yield per gram of
tissue in this series of experiments was
1.02 x 108 (s.d. 2-5 X 107, n = 34) with a
viability judged by vital staining with
erythrosin B to be at least 95%.
The cellularity of the B16 melanoma was
assessed by comparing the amount of DNA
in known numbers of isolated cells and in
weighed fragments of tissue using a colori-
metric assay (Ceriotti, 1952). An estimate of
4 x 108 cells per gram oftissue was obtained,
and it therefore appears that the trypsiniza-
tion procedure described above yields 20-25%
of the total cells from the tissue.
Cell-survival assay.-The survival of B16
melanoma cells was measured using a modifi-
cation ofthe soft-agar colony assay described
byCourtenay (1976). The cells weresuspended
at an appropriate concentration in Ham's
F12 culture medium supplemented with
20% foetal calf serum, antibiotics and 0.3%
Noble agar (Difco Laboratories). The final
cell concentration was then adjusted to
1 X 104/ml, with cells that had been exposed
to -30,000 rad of 60Co radiation in vitro.
Washed rat erythrocytes, at a final concentra-
tion of about 2-5 x 108/ml, were also added.
One-ml aliquots of this mixture were plated
into 30-mm plastic Petri dishes (Sterilin Ltd,
Richmond, England) which already contained
a solidified layer of 0-5% Noble agar in
culture medium. The dishes were incubated
at 37°C in a water-saturated atmosphere of
5% C02, 5% 02 and 90% N2 for 14 to 18
days and all colonies of more than 50 cells
were counted.
Plating efficiency (PE) was calculated by
dividing the number ofcolonies scored by the
number of cells plated. The standard error,
calculated from the colony counts of 3 to 6
dishes for each experimental point, was
usually less than5% ofthe mean. The control
PE varied from 0-25 to 0 55 over the period
during which this work was done. This
variation appeared to be mainly due to
differences in the potency of batches of rat
erythrocytes. PE and rate of colony growth
were both depressed when erythrocytes more
than 7 days old were used. The method was
capable of measuring PE down to about
0 0005. The ratio of PEs (treated/control) is
termed the surviving fraction (SF).
The fraction of 8urviving cells per tumour
following a given treatment was calculated
by deterniining the ratios of treated to
corresponding control values for tumour
weight, cell yield per gram of tissue and PE
respectively, and then using the relationship:
Fraction of Relative Relative
surviving =SFx cell X tumour
cells/tumour yield/g weight
RESULTS
Dose-re8ponse curves for 8ingle agent8
Dose-response studies were performed
in order to select suitable doses of each
agent for use in combination. Doses were
required which, when administered in
combination would be unlikely to reduce
the surviving fraction below 1 X 10-,
the limit of sensitivity of the cell survival
assay.
Assays were performed 24 h after admi-
nistration of each agent. None of the
agents produced any significant change
in tumour weight compared to untreated
controls.
VCR: The most marked effect of VCR
was upon cell yield per gram (Fig. 1A)
which decreased exponentially as the
dose was increased from 0-02 to 0-12 mg/
mouse. There was also a small decrease
(about 40%) in surviving fraction at
all doses studied (Fig. iB, solid symbols).
This resulted in an exponential decrease
in the fraction of surviving cells per
tumour (Fig. iB, open symbols). Follow-
ing exposure to high doses of VCR
(0-08 to 0 12 mg/mouse) for 24 h, tumours
were found to have developed large
liquefied central regions, and histological
studies demonstrated the presence of
large areas of haemorrhage and necrosis.
CP: The major effect of CP was on
surviving fraction, which was related to
dose by a curve decreasing exponentially
through 3 decades of survival (Fig. 2B,
solid symbols). There was also a small
reduction in cell yield at all doses (Fig.
2A). The curve relating fraction of
surviving cells per tumour to CP dose is
also exponential (Fig. 2B, open symbols).
Cell-size distribution analyses were per-
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FIG. 1. Dose-response and time-response curves for B16 melanoma treated with VCR. In the
dose-response study, relative cell yield per gram (A) surviving fraction (B, closed symbols) and
fraction of surviving cells per tumour (B, open symbols) were measured 24 h after treatment
with VCR at a range of doses. In the time-response study, relative cell yield per gram (C) surviving
fraction (D, closed symbols) and fraction of surviving cells per tumour (D, open symbols) were
measured at various times after treatment with VCR at a dose of 0- I mg/mouse. Each study
includes pooled data from at least 3 experiments.
formed on suspensions of cells prepared
from tumours treated with 3 and 6 mg
CP/mouse for 24 h, using a Coulter particle
counter and multi-channel analyser. The
mean cell volume was significantly
increased at these doses.
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FU: FU had no effect on cell yield per
gram at any ofthe doses studied (Fig. 3A).
There was, however, a gradual reduction
in surviving fraction and consequently
also in fraction of surviving cells per
tumour, at doses above 2 mg/mouse
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FIG. 2. Dose-response and time-response curves for B16 melanoma treated with CP. A dose of 3 mg CP/
mouse was used in the time-response study. Other details as in Fig. 1.
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FIG. 3.-Dose-response and time-response curves for B16 melanoma treated with FU. A dose of 5 mg FU/
mouse was used in the time-response study. Other details as in Fig. 1.
(Fig. 3B, closed and open symbols
respectively).
y-rays: This agent produced a pattern
of response very similar to that of CP.
There was a small reduction in cell yield
per gram of tumour at all radiation doses
studied (Fig. 4A) and a large effect on
surviving fraction, which decreased expo-
nentially over the dose range studied
(Fig. 4B, closed symbols). The netresponse
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in terms of fraction of surviving cells per
tumour was also exponential (Fig. 4B,
open symbols). Cell-size distribution
analysis indicated that there was a
significant increase in mean cell volume
24 h after exposure to 940 rad of y-rays.
For combination studies, 0 I mg VCR/
mouse + 3 mg CP/mouse and 5 mg FU/
mouse + 940 rad of y-rays were chosen.
At these doses VCR, CP and y-rays each
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FIG. 4. Dose-response and time-response curves for B16 melanoma treated with y-rays. A dose of 940 rad
was used in the time-response study. Other details as in Fig. 1.
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produced about one decade reduction in
the fraction of surviving cells per tumour,
while the FU dose chosen was the highest
which could be administered without acute
toxicity.
Time-response curvesfor single agents
Time-response studies were performed
to determine the time of minimum cell
survival, so that in combination studies
the assays would not be carried out
before both agents had achieved their
full cell-killing effects.
Each agent was given to groups of
mice at various times prior to a common
assay time. Since the tumour volume
doubling time was approximately 2 days,
mnice treated 48 hbefore assay hadtumours
which were only about half the size at
treatment of those treated just before
assay. At the time of assay, however,
there were no significant differences in
tumour weights between any of the
treated and untreated groups, indicating
that treatment had not retarded tumour
growth.
VCR: The major effects of 0 1 mg
VCR/mouse were; a rapid decrease in
SF to 5 x 10-1 by 5 h followed by a
much slower drop to 3 x 10-1 by 48 h
(Fig. ID, closed symbols) and a steady
drop in cell yield to about 1.8 X 10-1 by
20 h, where it remained until 48 h (Fig.
IC). The curve relating fraction of sur-
viving cells per tumour to time after VCR,
appears to be biphasic (Fig. ID, open
symbols). The proportion of surviving
cells fell rapidly to 8 x 10-2 by 20 h,
but during the next 30 h the rate of
decrease was much reduced.
CP: The most marked effect of 3 mg
CP/mouse was on SF which was reduced,
within 2 h, to about 1 x 10-1 and re-
mained at that level up to 48 h (Fig. 2D,
closed symbols). The effect on cell yield
was less, reaching 5 x 10-1 by 48 h
(Fig. 2C). The curve for fraction of
surviving cells per tumour is similar in
shape to that for SF, but the plateau
is at a lower level (7 x 10-2).
FU: 5 mg FU/mouse did not produce
any decrease in cell yield (Fig. 3C) but
SF was reduced within 3 h to 4 X 10-1,
and this was followed by a recovery
phase (Fig. 3D, closed symbols). The
response on a per tumour basis was
similar to that for SF (Fig. 3D, open
symbols).
y-rays: Exposure to 940 rad produced
an immediate fall of about one decade
in the fraction of surviving cells per
tumour and a further gradual fall during
the following 48 h (Fig. 4D, open symbols).
When assays were performed immediately
after y-irradiation, only SF was reduced
(Fig. 4D, closed symbols). At other times,
the effect in terms of cell survival per
tumour consisted of about one decade
reduction in SF plus a gradual fall in
cell yield per gram of tissue with increas-
ing time after treatment (Fig. 4C. For all
4 agents 24 h was chosen as a suitable and
convenient interval between drug admini-
stration and assay in combination studies.
Binary drug combination studies
Tumour-bearing animals were treated
with one agent at various times (up to
24 h) before or after a second agent, and
cell survival was measured 24 h after the
second agent was administered. The ob-
served response due to a combination was
compared with a theoretical survival level
calculated as a product of the fraction of
surviving cells per tumour obtained when
each agent was administered alone at
comparable times before assay. The
theoretical survival level is termed the
additive response (Vietti et al., 1971) and
assumes that the cell kill due to one
agent is independent of the cell kill due
to the other. Each combination experi-
ment included single-drug controls. The
additive responses are shown as dashed
lines in the combination Figs 5 and 6.
VCR + CP: The response obtained
when tumour-bearing mice were treated
with CP at various times before and after
VCR is shown in Fig. 5. Neither of these
sequences had any significant effect on
tumour weight, but cell yield and SF
were both considerably reduced. However,
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the reduction in cell yield was no greater
than that produced by VCR alone, and
the effect on SF was only slightly greater
than that produced by CP alone. In con-
sequence, the effect of the drug combina-
tion on the fraction of surviving cells per
tumour was greater than that of either
agent alone, but did not exceed the
*. - predicted additive level.
FU + y-rays: The combination of FU
and y-rays was found to reduce the
fraction of surviving cells per tumour to
. approximately 3 x 10-2 at all the
7dditive schedules of administration used (Fig. 6).
This effect was composed of a small
12 24 reduction in cell yield and a much larger
reduction in SF, but neither were signifi-
AFTER cantly different from that which could be
VOR (h) achieved with y-rays alone. Consequently,
tr obtained the response per tumour was never signifi-
CP (3 mg/ cantly greater than the additive response,
hbefore or nor significantly less than the response
ssays were
agent was due to y-rays alone.
response is
data from
F
FIG. 6. Cell survival per tumoui
following the administration of
mouse) at various times up to 2
or after y-rays (940 rad). 0th
as in Fig. 5.
DISCUSSION
We have explored the kinetics of cell
kill within B16 melanoma treated with
single doses of VCR, CP, FU and y-rays,
and have investigated the effects of the
combinations of VCR + CP and FU + y-
rays. As in any cell-survival studies on
solid tumours, our conclusions are based
upon a selected proportion of tumour
cells. The tumour-disaggregation proce-
. o . dure apparently yields about 25% of the
cells from untreated tumours and 25 to
-- - -- 55% of these are clonogenic under the
ditive conditions of the in vitro assay. It has
been assumed that the behaviour of the
cells obtained by the tumour-disaggrega-
tion procedure employed are representa-
tive of all cells in the intact tumour.
12 24 Cell kill by cytotoxic agents may be
revealed in two ways: by a fall in cell
:U AFTER yield and by a decrease in PE. The cell
ADIATION(h) yield was reduced by 3 of the agents used
r obtained in this study. However, in the cases of
FU (5 mg/ CP and y-rays the effect was small, and 24 h before cell-size distribution analyses indicated
Ler details
that both agents produced increases in
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the mean cell volume which could account
for this (Figs 2A and 4A). The formation
of giant cells in rapidly proliferating
tissues following exposure to CP has been
reported elsewhere (Custaldi et al., 1970).
VCR produced a much greater reduction
in cell yield (Fig. 1A) and we conclude
that this reflects drug-induced lysis of
cells within the tumour. We have observed
that tumours develop large liquefied
central regions following exposure to high
doses of VCR, which is consistent with
gross cell lysis. VCR has been shown to
have a cytotoxic effect on cultured
leukaemic lymphoblasts (Krishan and
Frei, 1975). Alternative explanations for
the decreased cell yield, such as greater
cell loss during the initial washes of the
tumour fragments or trypsin-induced lysis
of VCR-treated cells seem unlikely. Micro-
scopic examination of the supernatants
from the disaggregation procedure did not
reveal any marked increases in the levels
of either intact cells or cell debris.
Single-agent responses
When cell-survival assays were per-
formed 24 h after doses of VCR, CP or
y-rays, each agent produced an essentially
exponential curve relating fraction of
surviving cells per tumour to dose of
agent (Figs IB, 2B and 4B, open symbols).
No attempt has been made to fit a classical
bi-phasic air-breathing curve to the y-ray
experimental points presented in Fig. 4B
(open symbols), although these are con-
sistent with more detailed studies of Hill
and Stanley (1975) performed using alung-
colony assay. The curve for FU also had
an exponential region at higher doses, but
a shoulder was present at doses below
2 mg/mouse (Fig. 3B, open symbols).
The dose-response data for VCR and
CP against B16 melanoma are directly
comparable to those of Razek et al. (1974)
who found similarly shaped curves for
these drugs against leukaemia L1210 and
AKR lymphoma. However, B16 melanoma
appearstobeaboutone-quarter assensitive
to VCR, and about one-tenth assensitive to
CP, thaneitheroftheseleukaemic cell lines.
Our data for FU and y-rays may be
compared with that of Vietti et al. (1971)
and Bush and Bruce (1964) who used
transplanted AKR lymphoma. FU pro-
duced an exponential dose-survival curve
without a shoulder in the AKR lymphoma
system and is about 30 to 40 times more
sensitive to this agent than the B16
melanoma. AKR lymphoma is also about
4 x as sensitive as the B16 melanoma
to radiation.
The interpretation of time-response
curves is complicated by the fact that
tumours were treated at different times
prior to assay and therefore differed in
size at the time of treatment. Dose-
response experiments involving CY, VCR,
FU and y-rays have been performed on
tumours up to 4 x larger than those used
in this study and the curves obtained
were not significantly different from those
reported here. Thus, there is no reason to
believe that the cell-killing effects of
these agents vary significantly over the
tumour size range employed in the time-
course studies. Untreated tumours grew
with a volume-doubling time (Td) of
approximately 2 days; therefore tumours
treated 48 h before assay were about half
the size at treatment of those treated
just prior to assay. Ifno recovery occurred
during the period between treatment and
assay, the cell survival should therefore
be about half as much in groups treated
at 48 h as in those treated 1 h before
assay. This was observed with y-rays
(Fig. 4D, open symbols) and we conclude
that no significant proliferation of surviv-
ing cells occurred during the first 48 h
after irradiation. The data also confirm
the unpublished observation of W.U.
Shipley (referred to in Hill anJ Stanley,
1975) that B16 melanoma does not repair
potentially lethal damage. The response
following VCR, although complicated by
the decrease in cell yield per gram, also
suggests that no significant proliferation
occurred during the 48 h immediately
following drug treatment. At all times,
about half the extracted cells were unable
to form colonies in agar, and during the
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first 20 h there was a progressive cell lysis,
expressed as a decrease in cell yield. The
implication of this pattern of response is
that lysis rapidly follows reproductive
death. The tumour weight did not decrease
when cells underwent lysis, and fluid was
apparentlyretained, producinglarge lique-
fied central regions in these tumours. Due
to the experimental design employed, the
slow fall in the fraction of surviving cells
per tumour, which occurred between 20
and 48 h after VCR (Fig. ID, open
symbols), indicates that no additional
cell kill or recovery occurred during this
period. In contrast, the time-survival
curve for CP indicated that there was an
initial, very rapid cell-killing effect which
was complete after about 2 h and was
followed by a plateau (Fig. 2D, open
symbols). The existence of a plateau after
CP implies that recovery, which just
compensates for the size differences
between tumours at the times of treat-
ment, must have occurred. In comparison,
the cell survival per tumour measured
48 h after 5 mg FU/mouse was much
higher than that at 3 h, the time of
maximum cellkill (Fig. 3D, open symbols).
Forty-eight hours after treatment with
FU, the fraction of surviving cells per
tumour was nearly one decade higher than
would be expected if no recovery had
occurred. The observed recovery could
be due to proliferation of surviving cells
with a population doubling time (Td) of
about 16 h, although other factors such
as repair of potentially lethal damage
(PLD) might be involved. Hahn et al.
(1973) postulated repair ofPLD to explain
a similar effect seenwhenEMT6 mammary
sarcoma was treated with FU. It is
possible that no cell kill was detectable
24 h after low doses of FU (Fig. 3B)
because recovery was completed by that
time.
Combination studies
The primary objective of the present
work was to investigate whether the time-
dependent potentiation of cell killing
that has been observed by Vietti et al.
(1971) and Razek et al. (1974) using
leukaemic cells, also occurs in a non-
lymphoid experimental tumour. Our
results are firmly negative. For all
schedules of VCR + CP the degree of
cell lysis produced by VCR was not
appreciably affected by the addition of
CP, and the cell kill per tumour was
slightly less than the predicted additive
level (Fig. 5). Similarly, there was no
detectable schedule-dependent cell killing
effect in the combination of FU + y-rays
in B16 melanoma (Fig. 6). Cell yield and
surviving fraction changes due to the
combination were similar to the results
with y-rays alone, and the cell kill per
tumour was always slightly less than the
predicted additive level.
It is not clear why the combinations
of VCR + CP and FU + y-rays should
behave so differently against leukaemic
cell lines and the non-lymphoid B16
melanoma, although it is possible that
cell-kinetic differences between these
tumours may be responsible. Klein and
Lennartz (1974) demonstrated that VCR
can produce partial synchronization of
Ehrlich ascites cells in vivo, andfound that
there was a much greater reduction in
tumour growth-rate if CP was adminis-
tered when the synchronized cells reached
S phase, compared to administration
simultaneously with VCR. Furthermore,
FU may induce partial synchronization
of a cell population, making it more
sensitive to subsequent treatment with
X-rays (Vietti et al., 1971). However,
it seems likely that partial synchronization
would occur to a lesser extent in solid
tumours such as the B16 melanoma, than
in leukaemic and ascites tumours, perhaps
because they have more out-of-cycle
clonogenic cells. It has also been proposed
that VCR might increase the permeability
of leukaemic cells to CP, resulting in
greater uptake of CP and therefore a
larger cell kill (Razek et al., 1974) and
that FU may interfere with the repair of
sublethal damage if administered shortly
after X-rays (Vietti et al., 1971). However,
our results suggest that phenomena such
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as these are not likely to operate in the
B16 melanoma.
Our results with FU and y-rays are
consistent with the animal survival studies
of Wodinsky, Swiniarski and Venditti
(1975). They reported that y-rays (100-
600 rad) followed 1 h later by FU (3-75 to
15 mg/kg; -.0 075 to 0'3 mg/mouse) and
repeated for 10 days, starting one day
after intramuscular implantation of B16
melanoma homogenate, was not signifi-
cantly better than y-rays alone. The
results presented here are also consistent
with several clinical studies which indicate
that the combination of FU and low-LET
radiation is not significantly better than
radiation alone (Bleehen, 1973). Razek
et al. (1974) reported that the normal
mouse bone-marrow response was additive
when VCR and CP were given up to 24 h
apart in either sequence. Our failure to
find greater than additive cell kill in B16
melanoma implies that in this tumour
there is no differential therapeutic advan-
tage in the use ofthese two agents.
The combinations we have studied are
those which Valeriote and co-workers
found to produce very striking schedule
dependence and considerable potentiation
in leukaemic cell lines. However, in the
tumour used here we have been unable
to detect any schedule dependence or
potentiation. Our conclusion is therefore
that, in respect of potentiation, work on
leukaemic cell lines may be misleading
and may tend to overestimate the likeli-
hood of beneficial results from combina-
tion chemotherapy of solid tumours at a
clinical level.
We acknowledge the support and assist-
ance of Professor L. F. Lamerton and
Professor M. J. Peckham.
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